Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

ients maintain a higher ribavirin

dose. However, physicians could only prescribe EPO after the first dose

ribavirin reduction in the "IDEAL" trial. Since patients in the Peg-

Intron arms generally had smaller ribavirin dose reductions, this

introduces another potential bias and means those Peg-Intron patients

were potentially able to maintain a higher dose of ribavirin compared

to PEGASYS patients

About PEGASYS

PEGASYS was launched by Roche in 2002 and quickly became the leading treatment for patients with hepatitis C. It is indicated in combination with COPEGUS (ribavirin) for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA- approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and pa
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral ... results from its Phase IIa clinical trial of ... treat type 1 diabetes. The trial was conducted in ... a U.S. Food and Drug Administration (FDA) Investigational ...
(Date:10/22/2014)... Oct. 21, 2014 Influenza will affect as many ... the United States as high as ... to spread is from person to person in respiratory droplets ... serve way of death, but kills much fewer people each ... done by human fluids including sweat, saliva, blood and other ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 WHEN: ... EDTLOCATION: Online, complimentary registration available at: ... Leader Archana Vidyasekar and Visionary Innovation Research ... WiFi-like wireless electricity, self-assembling materials, nanobots and ... technologies which will transform our lives in ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... 25, 2014 Market Research ... Industry, 2009-2019 is a professional and in-depth ... Diagnostics industry. The report firstly reviews the ... classification, application and manufacturing technology. The report ... of Molecular Diagnostics listing their product specification, ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in ... after his combination drug therapy became too toxic. ... posted on the Surviving Mesothelioma website. , A ... Japan suggests that “maintenance therapy” with pemetrexed may be ... tolerate higher doses of cisplatin. , “Although the ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... developed that spot increased risks for certain cancers, one might ... screened. But a new study suggests that, at least ... found out their genes doubled their risk of colon cancer ... get screened. "It didn,t make any difference, not at ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... received a $1.5 million grant from the National Institutes ... major role in narcolepsy. ,Narcolepsy is a ... will further Yale research into narcolepsy and other disorders ... ,“The activity of these hypocretin cells is important ...
... a human tumor virus which causes Kaposi’s sarcoma and ... lymphomas with reported median survival time less than six ... of Helsinki have discovered that activation of the p53 ... lymphomas. ,The findings by the research group ...
... Center have found a new method for identifying suspect ... common acute infections in children. ,Traditionally, researchers ... down the virus or bacteria causing it. But that ... not be present in the blood or other easily ...
... to boycott the British Medical journal Lancet by a ... ‘warmongering’ attitude// of Lancet’s parent company Reed Elsevier. ... BMJ (formerly British Medical Journal) Fiona Godlee criticized that ... actually making money out of destroying health. ...
... conducted by Glenn Good and team from University of Missouri, ... of neurological injuries//. While it has been assumed all along ... study offers a new dimension to this issue. ... of their health. But the same quality is said to ...
... hospitals on the model of the All India Institute ... Bhubaneshwar, Jodhpur and Rishikesh under the Pradhan Mantri Swastha ... Welfare Anbumani Ramadoss has said. ,In a ... the Rajya Sabha, the upper House of the Indian ...
Cached Medicine News:Health News:$1.5 Million Grant to Yale for Narcolepsy-Neurotransmitter Study 2Health News:A Novel Treatment for KSHV-infected Lymphomas 2Health News:‘Fingerprints’ to Track Common Infections in Childr 2Health News:‘Fingerprints’ to Track Common Infections in Childr 3
... digital mobile imaging just got better ... and instrumentation. Now using,your C-arm you ... Easily Add Visualization and Navigation Technology, ... Intraoperative Decision Making, Provide a ...
... surgical navigation for Spine ... to integrate C-arm fluoroscopy ... It features automatic registration ... to the patient's anatomy, ...
... 20 years of CT engineering innovation and ... the forefront of the revolution in CT ... data at high speed with superb spatial ... extensive clinical experience and close cooperation with ...
... multislice CT scanners. In addition to the ... in an affordable Dual slice configuration. The ... advanced applications and high performance as the ... can be upgraded to Infinite Detector Technology, ...
Medicine Products: